NCT04991740View on ClinicalTrials.gov

A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 24, 2021

Primary Completion Date

February 9, 2023

Study Completion Date

February 9, 2023

Conditions
Neoplasms
Interventions
DRUG

JNJ-78306358

JNJ-78306358 will be administered.

Trial Locations (5)

8035

Hosp. Univ. Vall D Hebron, Barcelona

28040

Hosp. Univ. Fund. Jimenez Diaz, Madrid

28050

Hosp. Univ. Hm Sanchinarro, Madrid

31096

Rambam Medical Center, Haifa

64239

Sourasky Medical Center, Tel Aviv

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT04991740 - A Study of JNJ-78306358 in Participants With Advanced Stage Solid Tumors | Biotech Hunter | Biotech Hunter